Business
Eli Lilly cuts sales outlook after Incretin drug growth slows
Eli Lilly cuts its fourth-quarter revenue outlook due to slow growth in the incretin market, which raises insulin levels.
Eli Lilly cuts its fourth-quarter revenue outlook due to slow growth in the incretin market, which raises insulin levels.
